What Проктозан treats: Main Uses and Benefits

This combination preparation is used for anorectal disorders in situations where symptomatic support is needed for certain distressing symptoms. The medicine is commonly used to help manage symptoms in conditions such as hemorrhoids, anal fissures, and perianal eczema.

The focus is on providing targeted symptomatic relief. The preparation is utilized to help manage symptoms in situations where there is localized discomfort and inflammation.

Quick Fact: Relief for Combined Symptoms

Quick Fact: Relief for symptoms related to acute pain, swelling, and itching. This is applied when symptoms intensify, addressing symptom clusters that may become disruptive.

This preparation helps address symptom clusters that may become intense or disruptive, such as acute localized pain, burning, and intense anal itching (pruritus). It also assists with managing swelling and irritation linked to inflammatory or irritative states. Applied in contexts where additional management of discomfort is required, this supportive action contributes to easing the overall symptom load during symptomatic periods, providing relief that may assist with maintaining functional stability.

Проктозан (Proctosan), a preparation often used to relieve symptoms associated with hemorrhoids and other anal discomfort, is generally intended for adult use. Individuals considering its use should be aware of specific groups who must use caution or avoid the product entirely.

---

Groups Who Can Use Проктозан

Primary User Group	Conditions for Use
Adults	For temporary relief of symptoms such as itching, swelling, and pain associated with hemorrhoids.

---

Groups Who Cannot or Should Not Use Проктозан

Due to the active ingredients often found in similar formulations—which may include steroids (like hydrocortisone) and/or local anesthetics—consultation with a healthcare professional is crucial before use by certain individuals. The product is contraindicated and should be avoided in cases of sensitivity or allergy to any of the product's components.

Group	Restriction/Caution
Children	Use is not typically recommended unless directed by a healthcare practitioner.
Pregnant or Breastfeeding Individuals	Must consult a health professional before use to discuss potential risks.
Individuals with Specific Infections	Should be avoided if a tuberculosis, fungal, or viral infection is present in the affected area, as corticosteroid components may worsen these conditions.
Other Health Conditions	Individuals with conditions like bleeding or whose symptoms worsen or do not improve within 7 days should discontinue use and seek medical advice.

The official regulatory documents define the interaction profile of this preparation primarily through restrictions on co-administration with other locally or systemically acting agents. The profile includes several formal restrictions designed to prevent both cumulative local effects and increased systemic exposure.

Contraindicated and Restricted Combinations

Co-administration is restricted with other products containing amide-type local anesthetics or other topical NSAIDs to prevent cumulative local adverse reactions and potential systemic toxicity. The preparation is strictly contraindicated with oxidizing agents, such as certain nitrates, due to the documented risk of methemoglobin formation. Furthermore, co-administration with Class I antiarrhythmic agents carries a documented risk of pharmacodynamic interaction, potentially leading to additive cardiac depressant effects.

Exposure-Modifying Interactions

Pharmacokinetic interactions are documented concerning the Lidocaine component. Concomitant use with potent inhibitors of CYP1A2 and CYP3A4 enzymes (e.g., cimetidine) may increase the systemic concentration of Lidocaine, reducing its metabolic clearance. The risk associated with these interactions is officially heightened for patients with severe hepatic dysfunction due to their reduced capacity to metabolize the substance.

Administration Constraints

The regulatory information mandates separation of administration from any other rectally or anally applied medicinal products to ensure the correct local effect. Additionally, the use of external heat sources directly over the application area is restricted due to the potential for increasing systemic absorption.

Peripheral Neural Signal Interruption (Lidocaine)

The primary rapid mechanism involves the local anesthetic Lidocaine acting on the voltage-gated sodium channels ( Na V) of peripheral sensory nerves. By blocking these channels, the drug chemically prevents the nerve impulse from transmitting the signal, which results in the physiological change of failure of action potential conduction at the site of administration.

---

Anti-Inflammatory Mediator Modulation (Bufexamac)

The drug modulates the inflammatory response through the NSAID derivative Bufexamac, which exerts its action by inhibiting cyclooxygenase enzymes ( COX-1 and COX-2). This mechanism reduces the local biosynthesis of pro-inflammatory prostaglandins, contributing to a reduction in local swelling and decreasing vascular leakage and exudation.

---

Tissue Surface Consolidation and Protection (Bismuth Subgallate & TiO2)

The final component layer engages a physical and chemical barrier mechanism. Bismuth Subgallate precipitates tissue proteins to create an astringent, protective film that consolidates the surface, while Titanium Dioxide provides additional mechanical isolation. These mechanisms lead to tissue consolidation and mechanical isolation, acting as an additive function to the chemical-level modulation.

The administration of Проктозан involves its available dosage forms: the topical ointment and the suppository. The administration route is localized, intended for both external application to the perianal area and internal insertion into the rectum.

The standard adult dosing regimen involves applying a small quantity of the ointment or inserting one suppository per dose. The frequency of application is typically structured for use twice daily, once in the morning and once at night, with an optional additional application permissible after each bowel movement to ensure retention of the medication.

Administration Procedures

Prior to use, the affected area should be gently cleansed. For internal administration of the ointment, an applicator is attached to the tube. The procedure involves lubricating the applicator, then gently inserting it into the rectum. The dose is released by squeezing the tube while simultaneously removing the applicator. This procedural detail governs the correct placement of the dose. Suppositories, the other available form, are inserted upright into the rectum. The use of the preparation is generally constrained to short-term symptomatic courses and should not be continuous for longer than three weeks, establishing a defined duration for the treatment protocol.

Evidence for Symptomatic Management

The research framework supporting this preparation focuses on trials relevant to its active components, which was evaluated in studies designed to measure how patient-reported experiences change over time. The evidence base includes Randomized Controlled Trials (RCTs) that compared the components against an inactive base or against other common topical treatments.

For conditions like hemorrhoids and anal fissures, researchers examined specific outcomes related to physical discomfort, such as quantifying local pain intensity and analyzing symptomatic changes. Studies monitored outcomes reflecting the progress or course of the affected tissue over defined time intervals. The certainty level for the research base describing this general symptomatic approach is classified as Moderate.

Research Limitations and Areas of Uncertainty

The evidence level for the research base describing the use of the preparation for local inflammatory conditions (such as perianal eczema) is considered Low. The supporting evidence for the anti-inflammatory component is largely historical, and regulatory assessments in some jurisdictions have noted that these older studies did not meet the contemporary standards for demonstrating a clear evidence pattern.

Evidence is limited regarding the exact four-component fixed-dose combination, as available data often require extrapolation from trials focused on similar two- or three-agent preparations. Long-term effects are not fully established since follow-up durations were typically restricted to periods up to eight weeks. Furthermore, data for certain groups remain insufficient, meaning the results apply only to the symptomatic adults included in the primary trials.

Key Studies & References SUMMARY OF PRODUCT CHARACTERISTICS (SmPC) OF ANUDOL SUPPOSITORY (Containing Bismuth Subgallate and other agents)

Common questions about Проктозан (FAQ)

Q: Can Проктозан be used for anal fissures?

The therapeutic purpose of this preparation is the symptomatic management of anorectal discomfort, which includes conditions like hemorrhoids. Official documents note that the components have been used to manage symptoms of inflammation associated with anal fissures. The primary function is to relieve pain and swelling in the affected area.

Q: How long does it usually take to feel relief after starting Проктозан?

Relief can be expected to begin quickly after application. This is attributed to the local anesthetic component, Lidocaine, which has a primary rapid mechanism of action. This ingredient works by numbing the pain signals directly at the site of application.

Q: Is the burning or itching feeling described as a side effect common?

According to official product information, localized skin effects such as pruritus (itching), redness, and rash are frequently reported. These are localized skin reactions and are sometimes classified as common side effects.

Q: Does Проктозан interact with common pain relievers like ibuprofen?

Co-administration is restricted with other topical NSAIDs (non-steroidal anti-inflammatory drugs) to prevent cumulative local effects. The official documents note that the risk of additive adverse effects exists when the preparation is co-administered with other NSAIDs, including systemic ones like ibuprofen.

Q: Can I use Проктозан if I have other skin conditions in the area?

Regulatory documents restrict or contraindicate the application of the preparation to open wounds, broken skin, or areas with extensive damage. Furthermore, the Bufexamac component carries a high risk of contact allergic dermatitis, which is considered higher in patients with pre-existing skin conditions like certain forms of eczema.

Q: Can Проктозан be stored in the bathroom medicine cabinet?

The ointment and suppositories must be stored in a cool, dry place and kept within the temperature range specified on the packaging, generally below 25 C. Locations like bathroom medicine cabinets are often unsuitable for medication storage due to frequent fluctuations in heat and moisture that can affect product stability.

Q: What do official sources say about stopping the use of Проктозан?

Official instruction restricts continuous use to a short-term course, typically no longer than three weeks. Official product information states that use should be discontinued and medical consultation sought if symptoms worsen or do not show improvement within 7 days.

Q: Does Проктозан contain any steroids?

The active ingredients are officially listed as the local anesthetic Lidocaine, the NSAID derivative Bufexamac, and the protectant agents Bismuth Subgallate and Titanium Dioxide. The formulation does not contain a steroid (corticosteroid) component.

Q: Is there an expiration date on Проктозан, and does it matter if it passes?

The expiration date specifies the period during which the product is guaranteed to maintain its stability and effectiveness, assuming it has been stored correctly. Regulatory guidelines indicate that the product is not guaranteed to maintain its stability and effectiveness after the expiration date has passed.

Q: Is the ingredient called 'bufexamac' in Проктозан still commonly used?

The regulatory status of Bufexamac is a complex topic. For instance, the European Medicines Agency recommended revocation of its marketing authorizations in the European Union due to concerns over the high risk of serious contact allergic dermatitis and limited contemporary evidence of effectiveness.

Q: What happens if Проктозан gets onto surrounding, healthy skin?

Official safety warnings note a high risk of developing contact allergic dermatitis (ACD) from the Bufexamac component. This localized skin reaction can occur on the surrounding skin and has been documented to worsen with repeated exposures to the medication.

Q: Do regulatory bodies classify Проктозан as a safe medicine?

Regulatory reviews recognize the preparation for its symptomatic effectiveness in managing anorectal discomfort. However, they also highlight specific risks, such as a high risk of contact allergic dermatitis, and list several contraindications and restrictions that must be followed.

Q: Why is it important to follow the directions for applying Проктозан?

Following the specific directions for administration is the procedure defined to achieve the preparation’s intended local effect. The instructions are designed to achieve optimal retention of the preparation and ensure proper placement of the dose within the affected area.

Q: What is the main difference between Проктозан and other hemorrhoid creams I see advertised?

This preparation is defined in pharmacological reviews as a fixed-dose, multi-component topical therapy. This structure involves the strategic combination of four distinct agents—anesthetic, anti-inflammatory, and two protective substances—into a single formulation.

Q: Can men and women use Проктозан the same way?

Official documentation outlines use for adults generally. There are no specific differing administration or use instructions detailed between adult men and adult women.

Q: Does using Проктозан affect laboratory test results?

The Bismuth Subgallate component of the preparation is documented to cause a temporary black discoloration of the tongue and stools. This is a physical, expected non-serious side effect associated with the medication.

Q: Are the side effects of Проктозан permanent?

Side effects such as the temporary black discoloration of the stools are documented as non-permanent. Other common localized skin reactions are generally expected to resolve upon cessation of use.

Q: Are there different strengths of Проктозан available?

According to official product information, this preparation is a fixed-dose combination. This means the active ingredients are present in specific, defined quantities for both the ointment and suppository dosage forms.

How to Store and Dispose of Проктозан?

Storage conditions for suppositories and ointments are defined to maintain product stability and effectiveness until the expiration date. Official regulatory labeling specifies that suppositories must be stored within a specific temperature range, typically below 25 C or refrigerated between 2 C to 8 C, depending on the formulation, and must not be frozen. The ointment is generally required to be stored in a cool, dry place below 25 C. Both forms must be kept in their original containers to protect them from environmental factors like light and excessive moisture.

All medicinal products must be stored out of the sight and reach of children to prevent accidental ingestion. When disposing of unused or expired product, the official instruction is to discard the medicine according to local regulations. Regulatory bodies advise against flushing medicines down the toilet or putting them in household trash unless explicitly instructed to do so by the labeling, preferring drug take-back programs or safe disposal procedures at home.